Drug intelligence / Profile preview

ISU203

Development stage: Preclinical
Lead developer: ISU Abxis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

ISU203 is a novel monoclonal antibody developed for the treatment of Alzheimer's disease. It functions as an anti-acid sphingomyelinase (ASM) antibody, inhibiting ASM activity and regulating neuroinflammation. This mechanism indirectly inhibits amyloid-beta aggregation in the brain, which is associated with improved cognitive function and reduction of Th17-mediated neuroinflammation. Preclinical studies have shown that ISU203 facilitates removal of amyloid-β plaques and improves cognition in Alzheimer's disease models[1][5]. The drug has received a substance patent registration decision in Taiwan, indicating ongoing development efforts[2].

Targets

SMPD1 (Acid sphingomyelinase)

Beyond the preview

Go deeper on ISU203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ISU203.

Explore the full profile